ALK-Abello A/S
F:4AJ0
ALK-Abello A/S
F:4AJ0
Price:
26.98
EUR
-1.32%
Market Closed
Market Cap:
€5.4B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
ALK-Abello A/S
F:4AJ0
|
DK |
|
R
|
Ridley Corporation Ltd
ASX:RIC
|
AU |
|
PharmaCorp Rx Inc
XTSX:PCRX
|
CA |
|
MLG OZ Ltd
ASX:MLG
|
AU |
|
M
|
Metropole Television SA
F:MMT
|
FR |
|
Balkan Mining and Minerals Ltd
ASX:BMM
|
AU |
|
Oriental Payment Group Holdings Ltd
HKEX:8613
|
HK |
|
US Energy Corp
NASDAQ:USEG
|
US |
|
Amoeba SA
PAR:ALMIB
|
FR |
|
Driver Group PLC
LSE:DRV
|
UK |
|
F
|
FuJian YanJing HuiQuan Brewery Co Ltd
SSE:600573
|
CN |
|
H
|
Hill & Smith PLC
SWB:7HL
|
UK |
|
B
|
Best Pacific International Holdings Ltd
HKEX:2111
|
CN |
|
Tye Soon Ltd
SGX:BFU
|
SG |
Multiples-Based Value
The
Multiples-Based Value for
ALK-Abello A/S (4AJ0)
under the Base Case is
hidden
EUR.
Compared with the current market price of 26.98 EUR, the stock appears
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
4AJ0 Multiples-Based Value
LOCKED
Multiples Across Competitors
4AJ0 Competitors Multiples
ALK-Abello A/S Competitors
ALK-Abello A/S Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| DK |
|
ALK-Abello A/S
F:4AJ0
|
45.6B EUR | 7.2 | 38.1 | 22.6 | 27 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
883.9B USD | 13.6 | 42.8 | 28.9 | 30.8 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
585.2B USD | 6.2 | 21.8 | 15.2 | 18.6 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
237.5B GBP | 5.4 | 31.2 | 17.2 | 24.2 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.1 | 19.7 | 11.6 | 13.1 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
299.1B USD | 4.6 | 16.4 | 10.1 | 12.3 | |
| CH |
|
Novartis AG
SIX:NOVN
|
236.4B CHF | 5.4 | 21.8 | 13.5 | 17.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD | 102.3 | -81.1 | 375.3 | 941.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.4 | 10.3 | 7.6 | 9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
161B USD | 2.6 | 20.7 | 7.9 | 10.5 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
120B USD | 2.5 | 17 | 7.2 | 8.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
